Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adenosine deaminase (ADA) is an enzyme crucial for purine metabolism, catalyzing the irreversible deamination of adenosine and deoxyadenosine to inosine and deoxyinosine, respectively. It plays a key role in maintaining adenosine homeostasis and modulating immune responses. ADA deficiency leads to severe combined immunodeficiency disease (SCID), while elevated levels can be a diagnostic marker for diseases like tuberculosis. Inhibitors targeting this enzyme have therapeutic potential in immunosuppression, cancer therapy, and other applications.
Inhibition of adenosine deamination, leading to increased adenosine/deoxyadenosine levels or modulation of immune cell interactions.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adenosine Deaminase (ADA).